Greenwich Lifesciences Inc (GLSI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Greenwich Lifesciences Inc (GLSI) has a cash flow conversion efficiency ratio of -0.892x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.70 Million) by net assets ($5.27 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Greenwich Lifesciences Inc market capitalisation for the company's overall valuation and market capitalisation.
Greenwich Lifesciences Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Greenwich Lifesciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Greenwich Lifesciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Greenwich Lifesciences Inc ranked by their cash flow conversion efficiency. See GLSI cash flow to debt ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Flexsteel Industries Inc
NASDAQ:FLXS
|
0.119x |
|
Shandong Kehui Power Automation Co Ltd
SHG:688681
|
0.037x |
|
Toubani Resources Ltd
AU:TRE
|
-0.052x |
|
Kalyani Investment Company Limited
NSE:KICL
|
-0.001x |
|
Qudian Inc
F:1QU
|
N/A |
|
Silvaco Group, Inc. Common Stock
NASDAQ:SVCO
|
-0.066x |
|
RF Capital Group Inc
TO:RCG
|
0.017x |
|
AstroNova Inc
NASDAQ:ALOT
|
0.039x |
Annual Cash Flow Conversion Efficiency for Greenwich Lifesciences Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Greenwich Lifesciences Inc from 2017 to 2025. View Greenwich Lifesciences Inc (GLSI) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $353.22K | $-9.91 Million | -28.066x | -878.74% |
| 2024-12-31 | $2.53 Million | $-7.27 Million | -2.868x | -196.58% |
| 2023-12-31 | $6.70 Million | $-6.48 Million | -0.967x | -106.07% |
| 2022-12-31 | $13.21 Million | $-6.20 Million | -0.469x | -193.35% |
| 2021-12-31 | $26.83 Million | $-4.29 Million | -0.160x | -283.31% |
| 2020-12-31 | $27.63 Million | $-1.15 Million | -0.042x | -119.21% |
| 2019-12-31 | $-1.35 Million | $-293.27K | 0.217x | +1811.88% |
| 2018-12-31 | $-10.12 Million | $-114.95K | 0.011x | -19.82% |
| 2017-12-31 | $-8.53 Million | $-120.85K | 0.014x | -- |
About Greenwich Lifesciences Inc
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Ph… Read more